prikaz prve stranice dokumenta PLACE OF BIOLOGIC THERAPY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND ASSESSMENT OF ITS EFFICACY
  Download
PDF 127.23 KB
Scientific paper - Review paper
PLACE OF BIOLOGIC THERAPY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND ASSESSMENT OF ITS EFFICACY
Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, 67 (2013), 2; 155. urn:nbn:hr:184:143273
Krznarić, Željko; Štimac, Davor; Franjić, Neven; Kunović, Ana; Ljubas Kelečić, Dina

Cite this document

Krznarić, Ž., Štimac, D., Franjić, N., Kunović, A. & Ljubas Kelečić, D. (2013). PLACE OF BIOLOGIC THERAPY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND ASSESSMENT OF ITS EFFICACY. Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, 67. (2), 155. Retrieved from https://urn.nsk.hr/urn:nbn:hr:184:143273

Krznarić, Željko, et al. "PLACE OF BIOLOGIC THERAPY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND ASSESSMENT OF ITS EFFICACY." Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, vol. 67, no. 2, 2013, p. 155. https://urn.nsk.hr/urn:nbn:hr:184:143273

Krznarić, Željko, Davor Štimac, Neven Franjić, Ana Kunović and Dina Ljubas Kelečić. "PLACE OF BIOLOGIC THERAPY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND ASSESSMENT OF ITS EFFICACY." Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske 67, no. 2 (2013): 155. https://urn.nsk.hr/urn:nbn:hr:184:143273

Krznarić, Ž., et al. (2013) 'PLACE OF BIOLOGIC THERAPY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND ASSESSMENT OF ITS EFFICACY', Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, 67(2), p. 155. Available at: https://urn.nsk.hr/urn:nbn:hr:184:143273 (Accessed 13 September 2024)

Krznarić Ž, Štimac D, Franjić N, Kunović A, Ljubas Kelečić D. PLACE OF BIOLOGIC THERAPY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND ASSESSMENT OF ITS EFFICACY. Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske [Internet]. 2013 [cited 2024 September 13];67(2):155. Available at: https://urn.nsk.hr/urn:nbn:hr:184:143273

Ž. Krznarić, D. Štimac, N. Franjić, A. Kunović and D. Ljubas Kelečić, "PLACE OF BIOLOGIC THERAPY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND ASSESSMENT OF ITS EFFICACY", Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, vol. 67, no. 2, p. 155, 2013. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:143273. [Accessed: 13 September 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)PLACE OF BIOLOGIC THERAPY IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASES AND ASSESSMENT OF ITS EFFICACY
Title (croatian)MJESTO BIOLOŠKE TERAPIJE U LIJEČENJU UPALNIH BOLESTI CRIJEVA I PROCJENA NJENE DJELOTVORNOSTI
AuthorŽeljko Krznarić
MBZ: 75865
AuthorDavor Štimac
AuthorNeven Franjić
AuthorAna Kunović
AuthorDina Ljubas Kelečić
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Biological therapy (infliximab and adalimumab) in inflammatory bowel diseases is based on the IgG1 anti-TNF monoclonal antibodies with potent anti-inflammatory effects whose main mechanism of action is thought to be the induction of inflammatory cell apoptosis. Unquestionably, which arises from the most recent studies and meta-analysis, anti-TNF angents are an effective therapy primarily for the treatment of Crohn’s disease, but also ulcerative colitis, in different clinical situations. Infliximab has the most extensive clinical trial data, but other biological agents, such as adalimumab and certolizumab pegol appear to have similar benefits. In terms of future research, more long-term data are needed for both certolizumab pegol in Crohn’s disease and adalimumab in ulcerative colitis. Important role in the application of biological therapy is assessing its effectiveness and cost-benefit relationships that are estimated by regular follow-up. In the absence of response (primary and secondary) therapeutical options are dose increase, giving the drug in shorter intervals and substitution with other biological drug.
Abstract (croatian)
Biološka terapija (infliksimab i adalimumab) u upalnim bolestima crijeva temelji se na IgG1 anti-TNF monoklonalnim antitijelima sa snažnim protuupalnim učincima u podlozi kojih je apoptoza upalnih stanica. Neupitno je, a to proizlazi iz većine dosadašnjih studija i meta-analiza, da se radi o učinkovitoj terapiji u prvom redu za liječenje Crohnove bolesti (CB), ali i ulceroznog kolitisa u različitim kliničkim situacijama. Za sada postoji najviše podataka o učinkovitosti infliksimaba (IFX), ali istraživanja su pokazala kako i drugi anti-TNF lijekovi, prije svega adalimumab i certolizumab imaju slične učinke. Potrebna su daljnja istraživanja kako bi se utvrdila uloga certolizumab pegola u CB i adalimumaba u ulceroznom kolitisu. Važnu ulogu u primjeni biološke terapije ima procjena njene djelotvornosti te odnosa koristi-štetnosti koji se procjenjuju na osnovi redovitih pregleda. U slučaju izostanka odgovora (primarna i sekundarna nereaktivnost) preostaje povećanje doze, skraćenje intervala davanja lijeka te zamjena drugim biološkim lijekom.
Keywords (english)
Keywords (croatian)
Languagecroatian
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleActa medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske
Numberingvol. 67, no. 2, p. 155
p-ISSN1330-0164
e-ISSN1848-8897
URN:NBNurn:nbn:hr:184:143273
Publication2013
Document URLhttps://hrcak.srce.hr/111688
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-03-29 12:46:21